PTP Accounts Production v24.2.0.383 10048909 Board of Directors Board of Directors 1.1.23 31.12.23 31.12.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh100489092022-12-31100489092023-12-31100489092023-01-012023-12-31100489092021-12-31100489092022-01-012022-12-31100489092022-12-3110048909ns15:EnglandWales2023-01-012023-12-3110048909ns14:PoundSterling2023-01-012023-12-3110048909ns10:Director12023-01-012023-12-3110048909ns10:Director22023-01-012023-12-3110048909ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3110048909ns10:SmallEntities2023-01-012023-12-3110048909ns10:AuditExemptWithAccountantsReport2023-01-012023-12-3110048909ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3110048909ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3110048909ns10:FullAccounts2023-01-012023-12-3110048909ns10:RegisteredOffice2023-01-012023-12-3110048909ns5:CurrentFinancialInstruments2023-12-3110048909ns5:CurrentFinancialInstruments2022-12-3110048909ns5:ShareCapital2023-12-3110048909ns5:ShareCapital2022-12-3110048909ns5:RetainedEarningsAccumulatedLosses2023-12-3110048909ns5:RetainedEarningsAccumulatedLosses2022-12-3110048909ns5:ShareCapital2021-12-3110048909ns5:RetainedEarningsAccumulatedLosses2021-12-3110048909ns5:RetainedEarningsAccumulatedLosses2022-01-012022-12-3110048909ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-3110048909ns5:ComputerEquipment2023-01-012023-12-3110048909ns5:ComputerEquipment2022-12-3110048909ns5:ComputerEquipment2023-12-3110048909ns5:ComputerEquipment2022-12-3110048909ns5:CostValuation2022-12-3110048909ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3110048909ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-31
REGISTERED NUMBER: 10048909 (England and Wales)















Report of the Directors and

Unaudited Financial Statements for the Year Ended 31 December 2023

for

Central IVF Limited

Central IVF Limited (Registered number: 10048909)






Contents of the Financial Statements
for the Year Ended 31 December 2023




Page

Company Information 1

Report of the Directors 2

Chartered Accountants' Report 3

Income Statement 4

Statement of Financial Position 5

Statement of Changes in Equity 7

Notes to the Financial Statements 8


Central IVF Limited

Company Information
for the Year Ended 31 December 2023







DIRECTORS: S Barak
A Gamliel





REGISTERED OFFICE: Endeavour House
78 Stafford Road
Wallington
Surrey
SM6 9AY





REGISTERED NUMBER: 10048909 (England and Wales)





ACCOUNTANTS: PB Partners LLP
Endeavour House
78 Stafford Road
Wallington
Surrey
SM6 9AY

Central IVF Limited (Registered number: 10048909)

Report of the Directors
for the Year Ended 31 December 2023

The directors present their report with the financial statements of the company for the year ended 31 December 2023.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of the marketing and supply of IVF services.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 January 2023 to the date of this report.

S Barak
A Gamliel

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:





A Gamliel - Director


25 September 2024

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Central IVF Limited


In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Central IVF Limited for the year ended 31 December 2023 which comprise the Income Statement, Statement of Financial Position, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of Central IVF Limited, as a body, in accordance with the terms of our engagement letter dated 1 September 2016. Our work has been undertaken solely to prepare for your approval the financial statements of Central IVF Limited and state those matters that we have agreed to state to the Board of Directors of Central IVF Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Central IVF Limited and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Central IVF Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Central IVF Limited. You consider that Central IVF Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Central IVF Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






PB Partners LLP
Endeavour House
78 Stafford Road
Wallington
Surrey
SM6 9AY


25 September 2024

Central IVF Limited (Registered number: 10048909)

Income Statement
for the Year Ended 31 December 2023

2023 2022
£    £   

REVENUE 2,000,294 2,462,076

Cost of sales 819,951 1,100,255
GROSS PROFIT 1,180,343 1,361,821

Administrative expenses 665,222 367,460
515,121 994,361

Other operating income - 63,057
OPERATING PROFIT 515,121 1,057,418

Interest receivable and similar income 18,912 -
PROFIT BEFORE TAXATION 534,033 1,057,418

Tax on profit 125,590 201,042
PROFIT FOR THE FINANCIAL YEAR 408,443 856,376

Central IVF Limited (Registered number: 10048909)

Statement of Financial Position
31 December 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 2,205 2,132
Investments 5 1 1
2,206 2,133

CURRENT ASSETS
Debtors: amounts falling due within one year 6 26,182 173,396
Cash at bank 1,335,692 853,411
1,361,874 1,026,807
CREDITORS
Amounts falling due within one year 7 336,864 410,167
NET CURRENT ASSETS 1,025,010 616,640
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,027,216

618,773


CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 1,027,116 618,673
SHAREHOLDERS' FUNDS 1,027,216 618,773
1,027,216 618,773

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Central IVF Limited (Registered number: 10048909)

Statement of Financial Position - continued
31 December 2023


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on 25 September 2024 and were signed on its behalf by:




A Gamliel - Director



S Barak - Director


Central IVF Limited (Registered number: 10048909)

Statement of Changes in Equity
for the Year Ended 31 December 2023

Called up
share Retained Total
capital earnings equity
£    £    £   
Balance at 1 January 2022 100 115,762 115,862

Changes in equity
Dividends - (353,465 ) (353,465 )
Total comprehensive income - 856,376 856,376
Balance at 31 December 2022 100 618,673 618,773

Changes in equity
Total comprehensive income - 408,443 408,443
Balance at 31 December 2023 100 1,027,116 1,027,216

Central IVF Limited (Registered number: 10048909)

Notes to the Financial Statements
for the Year Ended 31 December 2023

1. STATUTORY INFORMATION

Central IVF Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The financial statements contain information about Central IVF Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Revenue recognition
Turnover represents income earned under contracts to provide professional services.

In respect of long-term contracts and contracts for on-going services, turnover represents the value of work done in the period, including estimates of amounts not invoiced. Turnover in respect of long-term contracts and contracts for on-going services is recognised by reference to the stage of completion.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Computer equipment - 20% per annum on cost

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.


Central IVF Limited (Registered number: 10048909)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2022 - 3 ) .

4. PROPERTY, PLANT AND EQUIPMENT
Computer
equipment
£   
COST
At 1 January 2023 3,477
Additions 799
At 31 December 2023 4,276
DEPRECIATION
At 1 January 2023 1,345
Charge for year 726
At 31 December 2023 2,071
NET BOOK VALUE
At 31 December 2023 2,205
At 31 December 2022 2,132

Central IVF Limited (Registered number: 10048909)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

5. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 January 2023
and 31 December 2023 1
NET BOOK VALUE
At 31 December 2023 1
At 31 December 2022 1

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors - 142,181
Amounts owed by subsidiary 11,512 5,319
Other debtors 14,670 14,670
Prepayments and accrued income - 11,226
26,182 173,396

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Bank loans and overdrafts 38,496 -
Trade creditors 89,569 87,483
Corporation tax 125,590 201,042
Social security and other taxes 4,643 3,027
Other creditors 8,744 8,097
Directors' current accounts 67,822 71,097
Accruals and deferred income 2,000 39,421
336,864 410,167

8. ULTIMATE CONTROLLING PARTY

The ultimate controlling parties are the directors, A Gamliel and S Barak.